Ipca Laboratories Limited (IPCALAB.NS)
INR 1378.2
(-1.64%)
INR 1378.2
(-1.64%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 13.29 Billion INR | 13.6% |
| 2022 | 10.52 Billion INR | -23.28% |
| 2021 | 13.78 Billion INR | -14.73% |
| 2020 | 16.09 Billion INR | 63.99% |
| 2019 | 9.76 Billion INR | 32.26% |
| 2018 | 7.49 Billion INR | 52.06% |
| 2017 | 4.94 Billion INR | 4.97% |
| 2016 | 4.6 Billion INR | 48.88% |
| 2015 | 3.14 Billion INR | -44.88% |
| 2014 | 5.72 Billion INR | -24.9% |
| 2013 | 7.63 Billion INR | 32.53% |
| 2012 | 5.77 Billion INR | 7.81% |
| 2011 | 4.75 Billion INR | 23.31% |
| 2010 | 4.19 Billion INR | 23.93% |
| 2009 | 3.48 Billion INR | 81.93% |
| 2008 | 1.89 Billion INR | -16.82% |
| 2007 | 2.28 Billion INR | 11.48% |
| 2006 | 2.06 Billion INR | 82.2% |
| 2005 | 1.12 Billion INR | -7.49% |
| 2004 | 1.21 Billion INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 3.92 Billion INR | 92.42% |
| 2023 FY | - INR | 13.6% |
| 2023 Q1 | 3.52 Billion INR | 62.11% |
| 2023 Q2 | 3.59 Billion INR | 2.09% |
| 2023 Q3 | 3.53 Billion INR | -1.68% |
| 2023 Q4 | 1.96 Billion INR | -44.52% |
| 2022 Q2 | 2.96 Billion INR | 1.9% |
| 2022 Q3 | 2.46 Billion INR | -16.88% |
| 2022 Q4 | 2.17 Billion INR | -11.88% |
| 2022 FY | - INR | -23.28% |
| 2022 Q1 | 2.91 Billion INR | 26.84% |
| 2021 Q4 | 2.29 Billion INR | -28.39% |
| 2021 Q1 | 4.35 Billion INR | 76.95% |
| 2021 Q2 | 3.83 Billion INR | -11.83% |
| 2021 Q3 | 3.2 Billion INR | -16.4% |
| 2021 FY | - INR | -14.73% |
| 2020 FY | - INR | 63.99% |
| 2020 Q4 | 2.45 Billion INR | -35.31% |
| 2020 Q3 | 3.8 Billion INR | 1.98% |
| 2020 Q2 | 3.72 Billion INR | -37.81% |
| 2020 Q1 | 5.99 Billion INR | 207.62% |
| 2019 FY | - INR | 32.26% |
| 2019 Q4 | 1.94 Billion INR | -32.65% |
| 2019 Q3 | 2.89 Billion INR | 3.57% |
| 2019 Q2 | 2.79 Billion INR | 28.43% |
| 2019 Q1 | 2.17 Billion INR | 25.9% |
| 2018 Q2 | 1.88 Billion INR | 41.5% |
| 2018 Q1 | 1.33 Billion INR | 0.0% |
| 2018 FY | - INR | 52.06% |
| 2018 Q4 | 1.72 Billion INR | -30.18% |
| 2018 Q3 | 2.47 Billion INR | 31.33% |
| 2017 FY | - INR | 4.97% |
| 2016 FY | - INR | 48.88% |
| 2015 FY | - INR | -44.88% |
| 2014 FY | - INR | -24.9% |
| 2013 FY | - INR | 32.53% |
| 2012 FY | - INR | 7.81% |
| 2011 FY | - INR | 23.31% |
| 2010 FY | - INR | 23.93% |
| 2009 FY | - INR | 81.93% |
| 2008 FY | - INR | -16.82% |
| 2007 FY | - INR | 11.48% |
| 2006 FY | - INR | 82.2% |
| 2005 FY | - INR | -7.49% |
| 2004 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Amrutanjan Health Care Limited | 681.59 Million INR | -1851.229% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.99 Million INR | -102235.334% |
| Caplin Point Laboratories Limited | 6.18 Billion INR | -115.07% |
| FDC Limited | 3.38 Billion INR | -292.852% |
| Gufic Biosciences Limited | 1.48 Billion INR | -798.32% |
| Hikal Limited | 2.69 Billion INR | -393.996% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | -93.824% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | -410.224% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -4527.12% |
| Medico Remedies Limited | 129.09 Million INR | -10202.183% |
| Nectar Lifesciences Limited | 1.53 Billion INR | -766.084% |
| Par Drugs and Chemicals Limited | 228.17 Million INR | -5728.666% |
| RPG Life Sciences Limited | 1.28 Billion INR | -937.807% |
| Sequent Scientific Limited | 549.8 Million INR | -2318.971% |
| Shilpa Medicare Limited | 2.58 Billion INR | -413.894% |
| Sigachi Industries Limited | 883.39 Million INR | -1405.494% |
| Themis Medicare Limited | 562.6 Million INR | -2263.906% |
| Unichem Laboratories Limited | 742.35 Million INR | -1691.526% |
| Venus Remedies Limited | 711.8 Million INR | -1768.43% |
| Wanbury Limited | 985.49 Million INR | -1249.532% |
| ZIM Laboratories Limited | 462.09 Million INR | -2778.075% |
| Lupin Limited | 36.96 Billion INR | 64.026% |
| Innova Captab Limited | 1.66 Billion INR | -697.184% |
| Ind-Swift Limited | 1.06 Billion INR | -1148.702% |
| Bajaj HealthCare Limited | 406.23 Million INR | -3173.82% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 78.475% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 571.296% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | -464.303% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -7502.06% |
| Morepen Laboratories Limited | 1.72 Billion INR | -670.559% |
| Laurus Labs Limited | 8 Billion INR | -66.119% |
| Aarti Drugs Limited | 3.24 Billion INR | -309.388% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | -93.789% |
| Alembic Limited | 1.11 Billion INR | -1091.349% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | -38.296% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | -17.241% |
| Vaishali Pharma Limited | 31.71 Million INR | -41839.705% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | -240.191% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -4011.637% |
| Jubilant Pharmova Limited | 8 Billion INR | -66.119% |
| Eris Lifesciences Limited | 6.98 Billion INR | -90.361% |
| Windlas Biotech Limited | 781.72 Million INR | -1601.312% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 90.388% |
| Lincoln Pharmaceuticals Limited | 1.34 Billion INR | -890.046% |
| Orchid Pharma Limited | 1.41 Billion INR | -837.126% |
| Albert David Limited | 1.04 Billion INR | -1172.164% |
| Hester Biosciences Limited | 539.47 Million INR | -2365.29% |
| Sakar Healthcare Limited | 393.26 Million INR | -3281.791% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | -184.349% |
| Procter & Gamble Health Limited | 3.07 Billion INR | -332.588% |
| Divi's Laboratories Limited | 25.43 Billion INR | 47.702% |
| Mankind Pharma Limited | 28.09 Billion INR | 52.662% |
| Neuland Laboratories Limited | 4.74 Billion INR | -180.097% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | -42.472% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 76.345% |
| Wockhardt Limited | 1.08 Billion INR | -1131.435% |
| Bal Pharma Limited | 345.59 Million INR | -3748.324% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 84.934% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | -799.204% |
| Alkem Laboratories Limited | 24.19 Billion INR | 45.032% |
| Valiant Laboratories Limited | 12.73 Million INR | -104299.874% |
| Ajanta Pharma Limited | 12.56 Billion INR | -5.842% |
| Bafna Pharmaceuticals Limited | 114.58 Million INR | -11506.87% |
| Aarey Drugs & Pharmaceuticals Limited | 45.16 Million INR | -29346.474% |
| Granules India Limited | 8.6 Billion INR | -54.577% |
| Medicamen Biotech Limited | 245.66 Million INR | -5313.783% |
| Brooks Laboratories Limited | 41.72 Million INR | -31771.885% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -2990.923% |
| Piramal Enterprises Limited | -3.86 Billion INR | 444.448% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 62.012% |
| NATCO Pharma Limited | 18.79 Billion INR | 29.239% |
| Suven Life Sciences Limited | -992.78 Million INR | 1439.622% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 16176.372% |
| Strides Pharma Science Limited | 3.76 Billion INR | -253.27% |
| Indoco Remedies Limited | 2.64 Billion INR | -402.426% |
| Alpa Laboratories Limited | 229.96 Million INR | -5683.372% |
| Lasa Supergenerics Limited | -65.08 Million INR | 20535.618% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 456.415% |